Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1978 2
1979 1
1980 1
1981 1
1982 1
1984 1
1985 2
1986 3
1988 2
1989 3
1990 1
1991 5
1992 3
1993 4
1994 7
1995 2
1996 6
1997 5
1998 9
1999 9
2000 6
2001 4
2002 7
2003 11
2004 10
2005 14
2006 14
2007 11
2008 15
2009 22
2010 15
2011 30
2012 31
2013 25
2014 29
2015 28
2016 25
2017 31
2018 25
2019 25
2020 29
2021 26
2022 17
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

463 results

Results by year

Filters applied: . Clear all
Page 1
Peripheral Edema: Evaluation and Management in Primary Care.
Patel H, Skok C, DeMarco A. Patel H, et al. Am Fam Physician. 2022 Nov;106(5):557-564. Am Fam Physician. 2022. PMID: 36379502
Validated decision rules, such as the Wells and STOP-Bang (snoring, tired, observed, pressure, body mass index, age, neck size, gender) criteria, can guide decision-making regarding the possibility of venous thromboembolic disease and obstructive sleep apnea, respectively. …
Validated decision rules, such as the Wells and STOP-Bang (snoring, tired, observed, pressure, body mass index, age, neck size, gende …
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Wolf J, et al. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787. N Engl J Med. 2020. PMID: 32877583 Clinical Trial.
The most frequently reported adverse events were peripheral edema (in 51%) and nausea (in 45%); these events were mostly of grade 1 or 2. ...The efficacy in MET-amplified advanced NSCLC was higher in tumors with a high gene copy number than in those with a low gene …
The most frequently reported adverse events were peripheral edema (in 51%) and nausea (in 45%); these events were mostly of gr …
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Paik PK, et al. N Engl J Med. 2020 Sep 3;383(10):931-943. doi: 10.1056/NEJMoa2004407. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469185 Free PMC article. Clinical Trial.
Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the patients, including peripheral edema in 7%. Adverse events led to permanent discontinuation of tepotinib in 11% of the patients. …
Adverse events of grade 3 or higher that were considered by investigators to be related to tepotinib therapy were reported in 28% of the pat …
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A …
The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis …
Pathophysiologic Processes and Novel Biomarkers Associated With Congestion in Heart Failure.
Pandhi P, Ter Maaten JM, Anker SD, Ng LL, Metra M, Samani NJ, Lang CC, Dickstein K, de Boer RA, van Veldhuisen DJ, Voors AA, Sama IE. Pandhi P, et al. JACC Heart Fail. 2022 Sep;10(9):623-632. doi: 10.1016/j.jchf.2022.05.013. JACC Heart Fail. 2022. PMID: 36049813 Free article.
OBJECTIVES: Using pathway and differential expression analyses, the authors aim to identify biological processes and biomarkers associated with congestion in HF. METHODS: A congestion score (sum of jugular venous pressure, orthopnea, and peripheral edema) was …
OBJECTIVES: Using pathway and differential expression analyses, the authors aim to identify biological processes and biomarkers associated w …
Crizotinib.
Heigener DF, Reck M. Heigener DF, et al. Recent Results Cancer Res. 2018;211:57-65. doi: 10.1007/978-3-319-91442-8_4. Recent Results Cancer Res. 2018. PMID: 30069759 Review.
In small series, efficacy is also reported in patients, whose tumours harbour a MET Exon 4 skipping mutation (approx. 3% of all NSCLC). Toxicities include visual impairment, nausea, peripheral edema, QT-prolongation and liver-enzyme elevation. Also, the occurrence o …
In small series, efficacy is also reported in patients, whose tumours harbour a MET Exon 4 skipping mutation (approx. 3% of all NSCLC). Toxi …
Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial.
Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Jagasia M, et al. Blood. 2020 May 14;135(20):1739-1749. doi: 10.1182/blood.2020004823. Blood. 2020. PMID: 32160294 Free PMC article. Clinical Trial.
Best ORR at any time was 73.2% (complete response, 56.3%). Responses were observed across skin (61.1%), upper (45.5%) and lower (46.0%) gastrointestinal tract, and liver (26.7%). ...The most common treatment-emergent adverse events were anemia (64.8%), thrombocytopenia (62 …
Best ORR at any time was 73.2% (complete response, 56.3%). Responses were observed across skin (61.1%), upper (45.5%) and lower (46.0 …
Crizotinib.
Heigener DF, Reck M. Heigener DF, et al. Recent Results Cancer Res. 2014;201:197-205. doi: 10.1007/978-3-642-54490-3_11. Recent Results Cancer Res. 2014. PMID: 24756793 Review.
The role in c-Met altered cancers needs to be determined. Toxicities include visual impairment, nausea, peripheral edema, QT-prolongation, and liver enzyme elevation. Also, the occurrence of renal cysts is reported. Fluorescence in situ hybridization (FISH) detectin …
The role in c-Met altered cancers needs to be determined. Toxicities include visual impairment, nausea, peripheral edema, QT-p …
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Blackhall F, et al. J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16. J Thorac Oncol. 2021. PMID: 33607312 Free article. Clinical Trial.
An independent data monitoring committee recommended that enrollment be discontinued because of the shorter OS observed with Rova-T compared with topotecan. Safety profiles for both drugs were consistent with previous reports. CONCLUSIONS: Compared with topotecan, which is …
An independent data monitoring committee recommended that enrollment be discontinued because of the shorter OS observed with Rova-T c …
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double-blind, placebo-controlled phase III study in Asian patients.
Baba M, Matsui N, Kuroha M, Wasaki Y, Ohwada S. Baba M, et al. J Diabetes Investig. 2019 Sep;10(5):1299-1306. doi: 10.1111/jdi.13013. Epub 2019 Feb 28. J Diabetes Investig. 2019. PMID: 30672128 Free PMC article. Clinical Trial.
The primary endpoint was the change from baseline in average daily pain score (ADPS) at week 14, defined as a weekly average of daily pain (0 = no pain to 10 = worst possible pain, for the past 24 h). ...The treatment-emergent adverse events observed were mostly mil …
The primary endpoint was the change from baseline in average daily pain score (ADPS) at week 14, defined as a weekly average of daily …
463 results